Skip to content

Current ratio at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
0.9×-0.2×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
1.5×-0.2×
Danaher logo
DanaherDHR
1.9×+0.4×
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
5.3×-1.0×
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
5.9×+0.5×
TEC
Bio-TechneTECH
4.5×+0.8×

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×

Where this comes from

Calculated from Cytek Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s current ratio?
Cytek Biosciences, Inc. (CTKB) reported current ratio of 4.7× in Q1 2026.
How has Cytek Biosciences, Inc.'s current ratio changed year-over-year?
Cytek Biosciences, Inc.'s current ratio decreased by 16.6% year-over-year, from 5.6× to 4.7×.
What is the long-term trend for Cytek Biosciences, Inc.'s current ratio?
Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s current ratio has grown at a -8.5% compound annual growth rate (CAGR), from 7.9× to 5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.